A role for IL-6 in rheumatoid arthritis has been proposed based upon the ability of the cytokine to activate inflammatory responses and osteoclastogenesis and is supported by positive clinical data obtained with the anti-IL-6 mAb tocilizumab in this patient population [23]. The gene discussed is IL6; the disease is rheumatoid arthritis.